Author

ZhongRui Ma

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

LINC00511 drives osimertinib resistance in LUAD via PERK kinase: A clinical biomarker with enzymatic therapeutic potential.

BACKGROUND Osimertinib resistance is a major challenge in the treatment of EGFR-mutated lung adenocarcinoma (LUAD), and the role of LINC00511 in this process remains unclear. METHODS We analyzed LINC00511 expression, patient prognosis, and its correlation with EIF2AK3 (encoding PERK) in LUAD using the GEPIA2 database...

Qingyang Lei, Jing Peng, Na Li et al. · Cellular Signalling · 0 citations

Open access Jul 2026

CRABP2 Promotes Lung Adenocarcinoma Through Retinoic Acid Pathway-Mediated NF-κB Activation.

BACKGROUND Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer and remains a major cause of cancer-related mortality. Despite advances in targeted therapies, tumor heterogeneity and acquired resistance frequently undermine clinical outcomes. This study aimed to identify novel oncogenic d...

Xi-Rui Zhu, Biao Fan, Qingyang Lei et al. · Frontiers in Bioscience · 0 citations